-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Elevated levels of uric acid (UA) are common in patients with type 2 diabetes (T2D) and can lead to gouty arthritis
.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) can reduce UA levels and may reduce the incidence of gout
diabetes
Recently, a research article was published in Diabetes Obesity & Metabolism, an authoritative journal in the field of metabolic endocrine diseases.
Researchers aimed to evaluate the effects of empagliflozin on UA levels, anti-gout drugs and gout attacks
.
The study included 7,020 T2D patients who were randomly assigned to the empagliflozin (10 or 25 mg) or placebo group
.
The researchers used a mixed linear model to evaluate the effects of empagliflozin and placebo on UA concentrations, and a Cox proportional hazard model to study the composite outcome of anti-gout drugs or gout attacks
Compared with placebo, empagliflozin can reduce serum UA levels: adjusted mean (95% CI) treatment difference at 52 weeks of treatment = -0.
37 (-0.
42, -0.
31) mg/dL; this is at baseline UA≥ It is more obvious in patients with 7.
0mg/dL and <7.
0mg/dL: the adjusted mean (95%CI) treatment difference at week 52 is -0.
56(-0.
68,-0.
43)mg/dL and -0.
30(- 0.
37,-0.
24) mg/dL
.
Among the 6607 patients who did not take anti-gout drugs at baseline, 5.
It can be seen that empagliflozin reduced UA levels and gout attacks or reduced the composite outcome of anti-gout drug prescriptions
.
These clinically significant results expand the utility of empagliflozin as a potential anti-gout treatment for T2D patients
Enpagliflozin reduced UA levels and gout attacks or reduced the composite outcome of anti-gout drug prescriptions
.
These clinically significant results expand the utility of empagliflozin as a potential anti-gout treatment for T2D patients
.
Original source: Empagliflozin URIC acid and Metabolism in Diabetes: A POST-hoc Analysis of Trial OUTCOME The EMPA-REG in this message
